Glypvilo

Glypvilo is a prescription oral medication that contains the active ingredient vildagliptin. It is marketed in the European Union and is typically supplied as tablets, although specific strength information is not provided in the source data. Vildagliptin belongs to the dipeptidyl peptidase‑4 (DPP‑4) inhibitor class and is used to improve glycemic control in adults with type 2 diabetes mellitus as part of a comprehensive treatment plan.

Glypvilo (vildagliptin) is indicated for the management of type 2 diabetes mellitus in adults.

- Improves blood glucose levels when used in combination with diet and exercise. - Can be prescribed as monotherapy or added to other oral antidiabetic agents such as metformin or sulfonylureas. - May be used in patients with inadequate glycemic control on other DPP‑4 inhibitors. - Provides glucose‑dependent insulin secretion without causing hypoglycemia when used alone. - Suitable for patients with renal impairment when dose adjustments are considered by a healthcare professional.

The safety profile of Glypvilo includes both common and less frequent adverse reactions that have been reported in clinical use.

Common: - Upper respiratory tract infection symptoms such as nasopharyngitis. - Headache or dizziness. - Gastrointestinal discomfort, including nausea or abdominal pain. - Mild skin reactions like rash or pruritus. - Joint pain or arthralgia. - Increased liver enzymes.

Serious: - Pancreatitis presenting with severe abdominal pain. - Severe hypersensitivity reactions, including angioedema or anaphylaxis.

When prescribing Glypvilo, clinicians should evaluate patient history and monitor specific clinical parameters to minimize risk.

- Assess renal function before initiation and periodically during therapy. - Use caution in patients with a history of pancreatitis. - Monitor liver enzymes if pre‑existing hepatic disease is present. - Adjust dose or avoid use in severe renal impairment as recommended by guidelines. - Counsel patients about the signs of hypoglycemia when combined with insulin or sulfonylureas. - Review concomitant medications that may affect glucose levels. - Consider pregnancy status; safety data are limited.

Glypvilo may interact with other medicines, altering its effectiveness or increasing the risk of adverse events.

Avoid: - Concurrent use with strong CYP2C19 inhibitors, which can increase vildagliptin plasma concentrations. - Co‑administration with other DPP‑4 inhibitors, as this provides no additional benefit and may raise toxicity risk.

Use with caution: - Combination with insulin or sulfonylureas, which can raise hypoglycemia risk. - Use alongside drugs that affect renal clearance, such as diuretics, requiring dose adjustment. - Concomitant use of medications that may cause pancreatitis, like GLP‑1 receptor agonists.